Skip to main
BMY

Bristol-Myers (BMY) Stock Forecast & Price Target

Bristol-Myers (BMY) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 24%
Hold 41%
Sell 6%
Strong Sell 0%

Bulls say

Bristol-Myers Squibb is expected to see positive financial performance in the coming years due to its strong focus on immuno-oncology and its leading position in drug development in this area. The company's heavy investment in research and development, coupled with its judicious spending and management's expertise, are likely to drive growth and contribute to its revenue and earnings. The updated model shows positive trends in total revenue and EPS, with our PT reflecting expectations for higher revenue and earnings driven by the approval of Zenbexus and management's continued support of the growth portfolio.

Bears say

Bristol-Myers Squibb is facing the challenge of high dependence on the US market, which could expose the company to potential political and regulatory risks. Additionally, while the company has a strong focus on immuno-oncology and growth products, the expected declines in legacy products and evenly phased OpEx in 2026 could limit earnings growth. However, with a catalyst-rich 2026 and potential for multiple expansion opportunities with upcoming clinical readouts and label expansions, the company may see investor interest and potential for profitability in the long term.

Bristol-Myers (BMY) has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 24% recommend Buy, 41% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bristol-Myers and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bristol-Myers (BMY) Forecast

Analysts have given Bristol-Myers (BMY) a Buy based on their latest research and market trends.

According to 17 analysts, Bristol-Myers (BMY) has a Buy consensus rating as of Sep 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $65.76, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $65.76, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bristol-Myers (BMY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.